Search

Your search keyword '"Gold, M R"' showing total 307 results

Search Constraints

Start Over You searched for: Author "Gold, M R" Remove constraint Author: "Gold, M R"
307 results on '"Gold, M R"'

Search Results

101. A comparison of T-wave alternans, signal averaged electrocardiography and programmed ventricular stimulation for arrhythmia risk stratification.

102. Primary prevention of sudden cardiac death with implantable cardioverter defibrillators: lessons learned from MADIT and MUSTT.

103. An alpha-helical cationic antimicrobial peptide selectively modulates macrophage responses to lipopolysaccharide and directly alters macrophage gene expression.

104. Customizing Medicaid managed care--California style.

105. Targets of B-cell antigen receptor signaling: the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase-3 signaling pathway and the Rap1 GTPase.

106. Electrophysiologic testing to identify patients with coronary artery disease who are at risk for sudden death. Multicenter Unsustained Tachycardia Trial Investigators.

107. Salmonella typhimurium infection and lipopolysaccharide stimulation induce similar changes in macrophage gene expression.

108. Synthesis and structure-affinity relationships of 1,3, 5-alkylsubstituted cyclohexylamines binding at NMDA receptor PCP site.

109. ICD therapy in the new millennium.

110. Short term escape rhythm characteristics after radiofrequency ablation of the atrioventricular junction.

111. Pacing for patients with congestive heart failure and dilated cardiomyopathy.

112. Signal-averaged isoharmonic body surface maps of patients with ischemic cardiomyopathy.

113. Cutting edge: cationic antimicrobial peptides block the binding of lipopolysaccharide (LPS) to LPS binding protein.

114. Sensing lead failure in implantable defibrillators: a comparison of two commonly used leads.

115. Optimization of transvenous coil position for active can defibrillation thresholds.

116. Tyrosine phosphorylation of shc in response to B cell antigen receptor engagement depends on the SHIP inositol phosphatase.

117. What drives Medicare managed care growth?

118. Left ventricular endocardial pacing: don't try this at home.

120. Cardiac arrhythmia: current therapy.

121. The B cell antigen receptor activates the Akt (protein kinase B)/glycogen synthase kinase-3 signaling pathway via phosphatidylinositol 3-kinase.

122. Protein kinase C-delta is a target of B-cell antigen receptor signaling.

123. Atrial defibrillation with a transvenous lead: a randomized comparison of active can shocking pathways.

124. Comparison of bipolar and integrated sensing for redetection of ventricular fibrillation.

125. Toward a broader view of values in cost-effectiveness analysis of health.

126. The effect of procainamide on T wave alternans.

127. Immediate and persistent complete heart block following a horse kick.

128. An 11-amino acid sequence in the cytoplasmic domain of CD40 is sufficient for activation of c-Jun N-terminal kinase, activation of MAPKAP kinase-2, phosphorylation of I kappa B alpha, and protection of WEHI-231 cells from anti-IgM-induced growth arrest.

129. Intravenous amiodarone suppression of electrical storm refractory to chronic oral amiodarone.

130. Optimization of ventricular pacing: where should we implant the leads?

131. The effect of shock configuration and delivered energy on defibrillation impedance.

132. Overdrive atrial pacing for conversion of atrial flutter: comparison of postoperative with nonpostoperative patients.

133. Rapid and efficient retrovirus-mediated gene transfer into B cell lines.

134. A new defibrillator discrimination algorithm utilizing electrogram morphology analysis.

135. Dendritic cell survival and maturation are regulated by different signaling pathways.

136. Inappropriate shocks from implanted cardioverter defibrillators caused by sensing of diaphragmatic myopotentials.

137. A comparison of pectoral and abdominal transvenous defibrillator implantation: analysis of costs and outcomes.

138. Reversible prolonged pacemaker failure due to electrocautery.

140. The effect of delivered energy on defibrillation shock impedance.

141. Effect of heart rate on T wave alternans.

142. Toward consistency in cost-utility analyses: using national measures to create condition-specific values.

143. Comparison of single- and dual-coil active pectoral defibrillation lead systems.

144. Effect of shock polarity on biphasic defibrillation thresholds using an active pectoral lead system.

145. Temporal stability of defibrillation thresholds with an active pectoral lead system.

146. Comparison of power- and temperature-guided radiofrequency modification of the atrioventricular node. Polaris Investigator Group.

147. Strength-duration relationship for human transvenous defibrillation.

148. Lead system optimization for transvenous defibrillation.

149. Effect of biphasic waveforms on transvenous defibrillation thresholds in patients with coronary artery disease.

150. Induction of atrial fibrillation with low-energy defibrillator shocks in patients with implantable cardioverter defibrillators.

Catalog

Books, media, physical & digital resources